Business Wire

Buyback and Burn of $MBG Unveiled as MultiBank Group Posts $209M H1 Revenue

20.8.2025 14:06:00 CEST | Business Wire | Press Release

Share

MultiBank Group, the world’s largest financial derivatives institution, has announced a strategic buyback and burn program for its $MBG Utility Token. Backed by strong H1 2025 results, with $209 million in revenue (up 20% year-on-year) and $170 million in profit, the measure is designed to enhance scarcity and drive long-term value for $MBG token holders.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250820831539/en/

Under the program, $MBG will be repurchased from the open market and permanently removed from circulation. The framework projects up to $58.2 million in buybacks within the first year and a cumulative $440 million over the initial five years. The Group describes the initiative as both a celebration of its H1 results and a gesture of gratitude to its worldwide client base.

Since its debut on July 22 across MultiBank.io, MEXC, Gate.io, and Uniswap, $MBG has surged to seven times its listing price, quickly becoming one of the most closely followed tokens globally.

Under the program, $MBG will be repurchased from the open market and permanently removed from circulation. The framework projects up to $58.2 million in buybacks within the first year and a cumulative $440 million over the initial five years. The Group describes the initiative as both a celebration of its H1 results and a gesture of gratitude to its worldwide client base.

“This is our way of thanking our customers and community for their trust,” said Naser Taher, Founder and Chairman of MultiBank Group. “We’ve established a solid foundation in traditional finance, and the rapid adoption of $MBG proves we’re equally ready to lead in digital assets. The token burn program is just the beginning, and we have more major announcements on the horizon.”

The $MBG token powers MultiBank’s four-pillar ecosystem:

  • MultiBank TradFi: The Group's traditional CFD powerhouse, which generated $362 million in revenue last year, allows traders to use $MBG for reduced fees and enhanced platform features.
  • MEX Exchange (Institutional ECN): This is a $23.7 billion institutional-grade hybrid FX and crypto ECN for emerging markets. $MBG automates settlement, reduces counterparty risk, and enables smart contract-based margin and delivery versus payment (DvP).
  • MultiBank.io (crypto exchange): Regulated across multiple jurisdictions, including the UAE and Australia, the platform offers both spot and leveraged trading. $MBG unlocks reduced costs along with additional utilities such as launchpad access, staking, and token participation opportunities.
  • MultiBank.io RWA: Built on Mavryk’s layer-1 blockchain, this division stems from the world’s largest real-world asset (RWA) tokenization initiative to date, a $3 billion real estate deal with MAG Lifestyle Development. $MBG holders receive fee discounts and early entry to projects.

Together, these four pillars are fueling MultiBank’s expansion, momentum that is also reflected in the Group’s growing community of more than 396,000 members on Telegram and over 280,000 followers across its X channels. With more than two million clients, 17+ financial licenses across five continents, and an unblemished compliance record since 2005, MultiBank Group is accelerating its blockchain and DeFi infrastructure to deliver more value-driven initiatives in the months ahead.

ABOUT MULTIBANK GROUP

MultiBank Group, established in California, USA in 2005, is a global leader in financial derivatives. With over 2 million clients in 100+ countries and a daily trading volume exceeding $35 billion, it offers a broad range of brokerage and asset management services. Renowned for innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group is regulated by 17+ top-tier financial authorities across five continents. Its award-winning platforms provide up to 500:1 leverage across Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 international awards for trading excellence and regulatory compliance.

For more information, visit MultiBank Group’s website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250820831539/en/

Contacts

Yazan Shakfeh
Global Head of Marketing
mohammad.shakfeh@multibankfx.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye